GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

If no other government comes forward to close the funding gap, we will face an alarming increase in transmission,' says Finn Jarle Rode, executive director of The Hepatitis Fund - Anadolu Ajansı ...

A newly updated clinical practice guideline offers healthcare practitioners vital evidence-based recommendations for managing ...

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing ... to developing potentially life-changing therapeutics for serious viral and liver ...

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.